Azithromycin: Nursing Drug Guide, QT Prolongation & NCLEX Review
Healthcare medication guide: screen QT risk, electrolytes, and QT-prolonging co-therapy before every dose—macrolides can prolong repolarization and cause fatal torsades de pointes, especially with warfarin, digoxin, uncorrected hypokalemia, or known long QT.
Azithromycin can prolong the QT interval and has been associated with torsades de pointes—a risk that can be fatal. Highest-risk patients include those with known QT prolongation, history of torsades, congenital long QT, bradyarrhythmias or uncompensated heart failure, uncorrected hypokalemia or hypomagnesemia, and anyone taking other QT-prolonging drugs (including class IA or III antiarrhythmics). Before every dose, complete medication reconciliation, review the MAR for QT-prolonging agents, check potassium and magnesium on the basic metabolic panel, and hold plus escalate if palpitations, syncope, or new hepatotoxic or allergic symptoms appear.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first and each subsequent dose, screen allergy to macrolides, QT-prolonging MAR entries, potassium and magnesium, and warfarin INR when applicable. Hold azithromycin and notify the prescriber or pharmacist for palpitations, syncope, supratherapeutic INR, hepatitis symptoms, serious rash, or watery diarrhea with fever.
Most common brand names
Azithromycin is widely available as generic tablets and oral suspension. Common brand names include Zithromax (tablets, suspension, and IV formulations in some markets). Verify route and strength on the MAR—oral products are not interchangeable with IV formulations without a new order.
Azithromycin is chemically related to erythromycin; cross-hypersensitivity to macrolides and ketolides is a labeled contraindication.
Why we give it — Indications
Azithromycin treats mild to moderate infections caused by susceptible organisms. Nurses commonly administer it for respiratory and ENT infections, including community-acquired pneumonia (when appropriate for oral therapy), acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and pharyngitis/tonsillitis as second-line therapy when first-line agents cannot be used.
| Use (adults, oral) | Detail |
|---|---|
| Community-acquired pneumonia | Mild community-acquired pneumonia in patients appropriate for oral therapy |
| Acute bacterial sinusitis | Due to susceptible organisms per labeling |
| Pharyngitis / tonsillitis | Alternative to first-line therapy when first-line cannot be used |
| Skin and soft tissue | Uncomplicated infections due to susceptible staphylococci or streptococci |
| Chlamydia / gonorrhea (adults) | Urethritis, cervicitis per approved regimens |
On a small screen, swipe or scroll sideways to see the full table.
Labeling states azithromycin should not be used in community-acquired pneumonia patients judged inappropriate for oral therapy because of moderate to severe illness or risk factors (e.g., cystic fibrosis, nosocomial infection, known or suspected bacteremia, elderly or debilitated patients, immunocompromised patients, significant health problems). Institutional protocols may vary.
How it works
Azithromycin is a macrolide antibacterial that binds the 50S ribosomal subunit and inhibits bacterial protein synthesis. Nursing focus is not only bacterial coverage but cardiac repolarization risk: labeling documents dose- and concentration-dependent QTc prolongation in healthy volunteers, which informs why electrolyte and drug-interaction screening belongs in every medication pass.
Dosing overview
Verify indication, weight (pediatrics), and renal/hepatic status against current prescribing information. Doses below are from FDA azithromycin tablet labeling; pediatric weight-based tables are extensive—use pharmacy or the full label for complete pediatric regimens.
Selected pediatric regimens (labeling)
| Indication | Dose | Duration |
|---|---|---|
| Otitis media | 30 mg/kg single dose or 10 mg/kg day 1 then 5 mg/kg days 2–5 | Per labeled 3- or 5-day regimen |
| Community-acquired pneumonia | 10 mg/kg day 1, then 5 mg/kg days 2–5 | 5 days (effectiveness of 3-day regimen not established in pediatrics for CAP) |
| Pharyngitis / tonsillitis | 12 mg/kg once daily | 5 days |
On a small screen, swipe or scroll sideways to see the full table.
Renal or hepatic adjustment: Not specified in the reviewed prescribing information for standard oral tablet dosing. Use caution in hepatic dysfunction; prior azithromycin-associated cholestatic jaundice is contraindicated.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for guidance.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Tmax (oral 500 mg) | ~2.2 hours (mean) | Peak exposure follows oral absorption; food does not affect absorption per labeling |
| Half-life | Long tissue half-life (labeling notes prolonged antigen exposure after discontinued therapy) | Allergic reactions may recur after drug stopped—observe per hypersensitivity warnings |
| QT effect | Dose-dependent QTc prolongation demonstrated in clinical pharmacology studies | Higher total daily exposure increases repolarization risk—screen co-therapy and electrolytes |
| Elimination | Biliary excretion is major route; renal elimination of unchanged drug is minor | Renal dose adjustment not detailed for oral tablets in reviewed labeling |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: azithromycin, erythromycin, any macrolide or ketolide; prior azithromycin-associated cholestatic jaundice or hepatic dysfunction
- MAR review for QT-prolonging drugs; cardiac history (long QT, torsades, heart failure, bradyarrhythmias)
- Recent basic metabolic panel including potassium and magnesium; ECG or rhythm assessment if clinically indicated
- If on warfarin: baseline INR and bleeding assessment; plan closer INR monitoring per labeling
- Myasthenia gravis history—labeling warns exacerbation and new onset of myasthenic syndrome
Contraindications
- Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide
- History of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Warfarin | May increase coagulation times / potentiate oral anticoagulants | Monitor INR or prothrombin time carefully during concurrent therapy |
| Digoxin | Macrolide class interactions reported; no dedicated azithromycin study in labeling | Careful monitoring advised when used concomitantly |
| Nelfinavir | Increased azithromycin exposure | Monitor for liver enzyme abnormalities and hearing impairment per labeling |
| QT-prolonging drugs / low K or Mg | Increased risk of arrhythmia and torsades | Hold and clarify with pharmacy when significant risk factors present |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets and suspension: May take with or without food per labeling. Use medication administration rights; shake suspension well before each dose. Complete the full prescribed course unless hold criteria are met.
- Confirm correct patient, drug, dose, route, and time; Z-Pak blister cards still require independent double-check
- Document administration and patient tolerance (GI effects, rash) on the MAR
- Neonates: labeling reports infantile hypertrophic pyloric stenosis after use up to 42 days of life—teach parents to report vomiting or feeding irritability
IV azithromycin: Not specified in the reviewed oral tablet prescribing information. Institutional protocols and product formulations may vary for IV route.
Expected therapeutic response
- Decreasing fever, improving cough, and reduced purulent respiratory secretions when treating susceptible respiratory infection
- Improving localized signs for skin or ENT infections per prescriber plan
- Stable vital signs and rhythm without new palpitations, dizziness, or syncope during therapy
- INR remains within prescriber goal when warfarin is co-prescribed
Red flags — Stop and act
Hold azithromycin and escalate immediately when serious toxicity is suspected.
- Palpitations, dizziness, syncope, or new arrhythmia—possible QT prolongation / torsades
- Signs of hepatitis: jaundice, dark urine, severe abdominal pain, profound fatigue—labeling requires immediate discontinuation
- Angioedema, bronchospasm, or systemic allergic reaction
- Serious skin reaction (rash progressing to mucosal involvement, blistering, or systemic symptoms)
- Watery diarrhea, abdominal pain, fever—evaluate for C. difficile colitis
- Worsening weakness or respiratory distress in myasthenia gravis
- Supratherapeutic INR or active bleeding on warfarin
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Diarrhea, nausea, vomiting, abdominal pain | Common in clinical trials | Supportive care; differentiate mild GI upset from CDAD or hepatitis |
| QT prolongation / arrhythmia | Postmarketing reports including torsades | Hold dose, obtain electrocardiogram (ECG) or rhythm strip per protocol, notify prescriber urgently |
| Hepatotoxicity | Severe and sometimes fatal cases reported | Stop drug, order liver function tests, notify prescriber immediately |
| Serious allergic / skin reactions | Includes angioedema, SJS, TEN, DRESS | Stop drug, treat per anaphylaxis or severe reaction protocol |
| CDAD | Reported with nearly all antibacterials | Isolation precautions per facility; stool studies per order |
| Myasthenia exacerbation | Reported postmarketing | Stop drug, notify neurology/prescriber, monitor respiratory status |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Labeling states adverse reactions at higher than recommended doses were similar to normal doses, particularly nausea, diarrhea, and vomiting.
Management
General symptomatic and supportive measures as required per labeling. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or toxicology services per facility protocol for severe overdose.
Look-alike / sound-alike and error prevention
- Azithromycin vs erythromycin—different agents but shared macrolide allergy risk
- Zithromax vs Zosyn (piperacillin-tazobactam)—verify drug name on MAR and blister pack
- Z-Pak day sequencing—day 1 often 500 mg, days 2–5 often 250 mg; wrong day strength is a common dispensing/administration error
- Single 1 g or 2 g doses—confirm indication (chlamydia vs gonorrhea) before administration
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| QT screen | Flag any new QT-prolonging psychotropic, antiemetic, or antiarrhythmic added during therapy |
| Electrolytes | Replete potassium and magnesium per prescriber before continuing therapy when levels are low |
| Warfarin patients | Schedule INR checks during and shortly after the course per pharmacy |
| GI teaching | Report watery diarrhea—not only “antibiotic stomach upset” |
| Commonly missed | Continuing azithromycin after palpitations; giving macrolide despite documented macrolide allergy |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Labeling notes greater sensitivity to torsades de pointes in some elderly patients |
| Cardiac disease / long QT | Higher fatal arrhythmia risk—avoid unless benefit clearly outweighs risk |
| Myasthenia gravis | Exacerbation and new myasthenic syndrome reported |
| Neonates (≤42 days) | IHPS reported—urgent evaluation if vomiting or feeding irritability |
| Pregnancy | Category B; no adequate human controlled studies—use only if clearly needed |
| Lactation | Excreted in breast milk in small amounts; caution in nursing women per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Heart rate, blood pressure, symptoms of palpitations, dizziness, syncope; electrocardiogram when ordered or clinically indicated
- Electrolytes (potassium, magnesium) when QT risk factors or diuretics present
- INR or prothrombin time when warfarin is concurrent
- GI tolerance, hydration, and stool character
- Signs of hepatotoxicity or allergic reaction (liver function tests per prescriber)
- Respiratory symptom trend for infection response
Document
- QT and interaction screening completed before first dose
- Day-by-day Z-Pak administration and any held doses with prescriber notification
- Patient teaching on diarrhea, rash, and when to seek urgent review
Patient teaching
- Take exactly as prescribed; for Z-Pak regimens, clarify that day 1 dose may differ from later days
- Report palpitations, fainting, yellowing skin or eyes, dark urine, severe abdominal pain, or trouble breathing immediately
- Report watery diarrhea, blood in stool, or abdominal cramping—even after stopping the antibiotic
- Ask the prescriber or pharmacist before starting new OTC medicines during therapy—interaction review is not fully detailed for all agents in the reviewed prescribing information
- Complete the course unless told to stop; do not share leftover antibiotics
- Breastfeeding patients: discuss risks and benefits with the prescriber—drug is present in milk in small amounts per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide
- Prior azithromycin-associated cholestatic jaundice or hepatic dysfunction
- New palpitations, syncope, or prescriber concern for QT prolongation
- Uncorrected significant hypokalemia or hypomagnesemia until repleted and cleared
- Signs of serious allergic reaction, severe rash, or hepatitis
- Watery diarrhea with fever or suspected CDAD pending evaluation
- Supratherapeutic INR or bleeding on warfarin until MDT review
- Acute worsening of myasthenia gravis symptoms
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Azithromycin is often started quickly for respiratory infections—exactly when nurses must slow down for QT and interaction screening.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right day of Z-Pak sequence
- Macrolide allergy and prior azithromycin hepatotoxicity reviewed
- QT-prolonging MAR entries and electrolytes reviewed
- Warfarin patients: INR trend checked before each dose when ordered
2. Safety badge
QT-risk macrolide — cardiac and interaction screening requiredAlthough not a traditional high-alert medication in all institutions, labeling documents fatal QT risk—treat interaction and electrolyte review with the same rigor as institutional high-alert workflows.
3. Hold and question rules
- Any new palpitation or syncope → hold next dose and obtain rhythm assessment per protocol
- Potassium below institutional threshold → notify prescriber before giving macrolide
- INR above goal with bleeding signs → hold and contact pharmacy
4. Critical teach-back questions
- “What heart or fainting symptoms should you report?” (Patient should name palpitations, dizziness, or fainting.)
- “What type of diarrhea needs urgent review?” (Patient should describe watery, frequent stools, fever, or blood.)
5. Care coordination
Pharmacist: QT drug interaction review, warfarin INR plan, Z-Pak sequencing errors
Prescriber: Alternative antibiotic if QT or allergy risk outweighs benefit; hepatotoxicity or CDAD management
🧠 Quick mental checklist
- Does this patient have QT risk factors or QT-prolonging drugs on the MAR?
- What are today’s potassium and magnesium results?
- Is warfarin co-prescribed—and when was the last INR?
- Any macrolide allergy or prior azithromycin liver injury?
- Has the patient developed palpitations, jaundice, severe rash, or watery diarrhea?
Azithromycin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for azithromycin QT and interaction safety using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), INR trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Azithromycin 250 mg PO daily (day 2 of 5-day CAP regimen; 500 mg given yesterday)
- Warfarin 5 mg PO daily — due 1800
- Digoxin 0.125 mg PO daily — given 0800
- Furosemide 40 mg PO daily — given 0800
- Admission INR 2.3 (goal 2.0–3.0)
- Today BMP: potassium 3.1 mEq/L; magnesium 1.6 mg/dL; creatinine 1.0 mg/dL
- INR today 3.8 (morning draw)
- LFTs pending after patient reported new bruising
- BP 108/62 mmHg; HR 112 irregular; RR 18; SpO2 96% on room air
- Temperature 37.1 °C
- Patient reports intermittent palpitations and lightheadedness when standing
- 74-year-old with mild CAP started on azithromycin yesterday; history of atrial fibrillation and long QT on prior ECG (in chart)
- New ecchymosis on forearms; no fall reported
- Pharmacy sticker on chart: “Screen QT drugs and electrolytes with macrolide”
- Patient asks why heart is “racing” since second antibiotic dose
Answer key & rationale
Frequently asked questions
Why is QT prolongation the main nursing safety concern with azithromycin?
Prescribing information reports prolonged cardiac repolarization and QT interval with macrolides including azithromycin, with postmarketing cases of torsades de pointes that can be fatal. Risk rises with known long QT, torsades history, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, heart failure, and coadministration of other QT-prolonging drugs.
When should a nurse hold azithromycin?
Hold for hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide; prior azithromycin-associated cholestatic jaundice or hepatic dysfunction; new serious allergic or skin reaction; signs of hepatitis; watery diarrhea with fever suggesting C. difficile; palpitations or syncope with QT risk factors; or unresolved interaction with warfarin when INR is supratherapeutic.
Does azithromycin interact with warfarin?
Labeling states concomitant azithromycin may potentiate oral anticoagulants such as warfarin and increase coagulation times. Prothrombin time or INR should be carefully monitored while both drugs are used.
What adverse effects matter most for nurses?
Priority nursing concerns include QT prolongation and arrhythmias, serious allergic and hepatotoxic reactions, C. difficile-associated diarrhea, exacerbation of myasthenia gravis, and common GI effects (nausea, vomiting, diarrhea, abdominal pain) that may mask serious toxicity.
Is azithromycin safe in pregnancy and breastfeeding?
Prescribing information lists pregnancy category B with no adequate controlled studies in humans—use only if clearly needed. Azithromycin is excreted in human breast milk in small amounts; caution is advised when administered to nursing women per labeling.
References
- U.S. National Library of Medicine. Azithromycin tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b998c33-00dd-4f8d-88b9-0cdf609c3c45
- U.S. National Library of Medicine. Zithromax (azithromycin) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33d6f313-c763-5fbd-e054-00144ff8d46c
- Drugs and Lactation Database (LactMed). Azithromycin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK380897/
- U.S. National Library of Medicine. Azithromycin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a697037.html
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.